Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

USPTO grants NOA to Precision engineered meganucleases patent

The US Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) to Precision BioSciences' patent application 13/245,607 (the '607 Application) regarding the engineered meganucleases.

The patent relates to methods of cleaving a target DNA site in a cell using an engineered meganuclease, utilizing as a part of Precision’s DNE genome engineering technology.

Precision BioSciences Scientific Development VP and the ‘607 application co-inventor Derek Jantz said they welcome the decision by the PTO allowing these claims, which cover their inventions of methods for cleaving DNA.

"Importantly, the claimed methods include the use of engineered features that are a key aspect of Precision’s award-winning DNE approach to genome engineering," Jantz said.